Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Controlled Release Technologies for Chronotherapy: Current Status and Future Perspectives

Author(s): Bhavana B. Bhat, Chetan H. Mehta, Akhil Suresh, Varalakshmi Velagacherla and Usha Y. Nayak*

Volume 29, Issue 14, 2023

Published on: 08 May, 2023

Page: [1069 - 1091] Pages: 23

DOI: 10.2174/1381612829666230423144232

Price: $65

Open Access Journals Promotions 2
Abstract

The expression “as sure as night follows a day” emulates those certain cycles in the environment that are always stable. Circadian rhythms are a group of processes that occur within the body in synchronisation with the external factors in a 24 h cycle. Changes in lifestyle and work shifts have disrupted these stable rhythms, which is a leading cause of lifestyle diseases. Associations between these biological clocks and diseases are abundant. However, it is also known that certain drugs work more efficiently and have minimum toxicity when given during a particular phase of the circadian cycle. Chronotherapeutics focuses on treating diseases according to the endogenous processes which mediate xenobiotic metabolism and drug response at a cellular level. Therefore, treatment of those diseases that show aggravation of symptoms according to the circadian rhythms at a particular time is highly beneficial by chronotherapy. In this article, we have emphasised how the changes in rhythms caused diseases and how chronotherapeutic approaches such as controlled drug release technologies can be a better option for these circadian manipulations that seem to influence all types of disease conditions.

Keywords: Biological rhythms, circadian rhythms, chronobiology, chronopharmacokinetics, chronotherapeutics, controlled release systems, synchronization.

Next »
[1]
Vitaterna MH, Takahashi JS, Turek FW. Overview of circadian rhythms. Alcohol Res Heal 2001; 25: 93.
[2]
Kuhlman SJ, Craig LM, Duffy JF. Introduction to Chronobiology. Cold Spring Harb Perspect Biol 2018; 10(9): a033613.
[http://dx.doi.org/10.1101/cshperspect.a033613] [PMID: 29038118]
[3]
Pérez JAM. An introduction to chronobiology. In: Chronobiol Obes. Springer: New York 2013; pp. 11-28.
[http://dx.doi.org/10.1007/978-1-4614-5082-5_2]
[4]
Roenneberg T, Klerman EB. Chronobiology. Somnologie 2019; 23(3): 142-6.
[http://dx.doi.org/10.1007/s11818-019-00217-9] [PMID: 34377083]
[5]
Lévi F, Okyar A. Circadian clocks and drug delivery systems: Impact and opportunities in chronotherapeutics. Expert Opin Drug Deliv 2011; 8(12): 1535-41.
[http://dx.doi.org/10.1517/17425247.2011.618184] [PMID: 22097903]
[6]
Çalıyurt O. Role of chronobiology as a transdisciplinary field of research: Its applications in treating mood disorders. Balkan Med J 2017; 34(6): 514-21.
[http://dx.doi.org/10.4274/balkanmedj.2017.1280] [PMID: 29072179]
[7]
Helm B, Visser ME, Schwartz W, et al. Two sides of a coin: Ecological and chronobiological perspectives of timing in the wild. Philos Trans R Soc Lond B Biol Sci 2017; 372(1734): 20160246.
[http://dx.doi.org/10.1098/rstb.2016.0246] [PMID: 28993490]
[8]
Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science 2010; 330(6009): 1349-54.
[http://dx.doi.org/10.1126/science.1195027] [PMID: 21127246]
[9]
McClung CR. Plant circadian rhythms. Plant Cell 2006; 18(4): 792-803.
[http://dx.doi.org/10.1105/tpc.106.040980] [PMID: 16595397]
[10]
Reddy S, Reddy V, Sharma S. Physiology, Circadian Rhythm. StatPearls 2021.
[11]
Huang W, Ramsey KM, Marcheva B, Bass J. Circadian rhythms, sleep, and metabolism. J Clin Invest 2011; 121(6): 2133-41.
[http://dx.doi.org/10.1172/JCI46043] [PMID: 21633182]
[12]
Millar-Craig M, Bishop C, Raftery EB. Circadian variation of blood-pressure. Lancet 1978; 311(8068): 795-7.
[http://dx.doi.org/10.1016/S0140-6736(78)92998-7] [PMID: 85815]
[13]
Reddy GS, Nayak UY, Deshpande PB, Mutalik S. Gastroretentive pulsatile release tablets of lercanidipine HCl: Development, statistical optimization, and in vitro and in vivo evaluation. Sci World J 2014; 2014: 421931.
[http://dx.doi.org/10.1155/2014/421931]
[14]
Lambert EA, Chatzivlastou K, Schlaich M, Lambert G, Head GA. Morning surge in blood pressure is associated with reactivity of the sympathetic nervous system. Am J Hypertens 2014; 27(6): 783-92.
[http://dx.doi.org/10.1093/ajh/hpt273] [PMID: 24436322]
[15]
Yeung J, Mermet J, Jouffe C, et al. Transcription factor activity rhythms and tissue-specific chromatin interactions explain circadian gene expression across organs. Genome Res 2018; 28(2): 182-91.
[http://dx.doi.org/10.1101/gr.222430.117] [PMID: 29254942]
[16]
Lamia KA, Storch KF, Weitz CJ. Physiological significance of a peripheral tissue circadian clock. Proc Natl Acad Sci 2008; 105(39): 15172-7.
[http://dx.doi.org/10.1073/pnas.0806717105] [PMID: 18779586]
[17]
Eckel-Mahan K, Sassone-Corsi P. Metabolism and the circadian clock converge. Physiol Rev 2013; 93(1): 107-35.
[http://dx.doi.org/10.1152/physrev.00016.2012] [PMID: 23303907]
[18]
Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: Organization and coordination of central and peripheral clocks. Annu Rev Physiol 2010; 72(1): 517-49.
[http://dx.doi.org/10.1146/annurev-physiol-021909-135821] [PMID: 20148687]
[19]
Mathews TJ, Curtin S. When are babies born: Morning, noon, or night? Birth certificate data for 2013. NCHS Data Brief 2015; 200: 200.
[20]
Krishna M, Semwal B, Neelam S, Ruqsana K, Shravan P, Bhowmik D. Chronopharmacology: As a therapy for cardiovascular disease. Pharma Innov J 2012; 1: 06-15.
[21]
van Diemen JJK, Fuijkschot WW, Wessels TJ, Veen G, Smulders YM, Thijs A. Evening intake of aspirin is associated with a more stable 24-h platelet inhibition compared to morning intake: A study in chronic aspirin users. Platelets 2016; 27(4): 351-6.
[http://dx.doi.org/10.3109/09537104.2015.1107536] [PMID: 26599376]
[22]
Khashkhashi-Moghadam S, Ezazi-Toroghi S, Kamkar-Vatanparast M, et al. Novel perspective into the interaction behavior study of the cyanidin with human serum albumin-holo transferrin complex: Spectroscopic, calorimetric and molecular modeling approaches. J Mol Liq 2022; 356: 119042.
[http://dx.doi.org/10.1016/j.molliq.2022.119042]
[23]
Sharifi-Rad A, Mehrzad J, Darroudi M, Saberi MR, Chamani J. Oil-in-water nanoemulsions comprising Berberine in olive oil: Biological activities, binding mechanisms to human serum albumin or holo-transferrin and QMMD simulations. J Biomol Struct Dyn 2021; 39(3): 1029-43.
[http://dx.doi.org/10.1080/07391102.2020.1724568] [PMID: 32000592]
[24]
Tataroglu O, Emery P. Studying circadian rhythms in Drosophila melanogaster. Methods 2014; 68(1): 140-50.
[http://dx.doi.org/10.1016/j.ymeth.2014.01.001] [PMID: 24412370]
[25]
Fenske MP, Nguyen LAP, Horn EK, Riffell JA, Imaizumi T. Circadian clocks of both plants and pollinators influence flower seeking behavior of the pollinator hawkmoth Manduca sexta. Sci Reports 2018; 81(8): 1-13.
[http://dx.doi.org/10.1038/s41598-018-21251-x]
[26]
Xie Y, Tang Q, Chen G, et al. New insights into the circadian rhythm and its related diseases. Front Physiol 2019; 10: 682.
[http://dx.doi.org/10.3389/fphys.2019.00682] [PMID: 31293431]
[27]
Adam D. Emerging science of chronotherapy offers big opportunities to optimize drug delivery. Proc Natl Acad Sci 2019; 116(44): 21957-9.
[http://dx.doi.org/10.1073/pnas.1916118116] [PMID: 31662491]
[28]
Larry J. Hormonal Rhythms and Pulsatility In:. Endocrinology. 2016.
[29]
Smolensky MH, Portaluppi F. Chronopharmacology and chronotherapy of cardiovascular medications: Relevance to prevention and treatment of coronary heart disease. Am Heart J 1999; 137(4): S14-24.
[http://dx.doi.org/10.1016/S0002-8703(99)70392-3] [PMID: 10097242]
[30]
Dernie F, Adeyoju D. A matter of time: Circadian clocks in osteoarthritis and the potential of chronotherapy. Exp Gerontol 2021; 143: 111163.
[http://dx.doi.org/10.1016/j.exger.2020.111163] [PMID: 33227402]
[31]
Thosar SS, Butler MP, Shea SA. Role of the circadian system in cardiovascular disease. J Clin Invest 2018; 128(6): 2157-67.
[http://dx.doi.org/10.1172/JCI80590] [PMID: 29856365]
[32]
Selfridge JM, Gotoh T, Schiffhauer S, et al. Chronotherapy: Intuitive, sound, founded…but not broadly applied. Drugs 2016; 76(16): 1507-21.
[http://dx.doi.org/10.1007/s40265-016-0646-4] [PMID: 27699644]
[33]
Buurma M, van Diemen JJK, Thijs A, Numans ME, Bonten TN. Circadian rhythm of cardiovascular disease: The potential of chronotherapy with aspirin. Front Cardiovasc Med 2019; 6: 84.
[http://dx.doi.org/10.3389/fcvm.2019.00084] [PMID: 31281821]
[34]
Vijay K, Kumar KM, Ajay B, Nocturnal AAIMBC. Nocturnal asthma and its management by chronotherapy. World J Pharm Pharm Sci 2019; 8: 570-85.
[35]
Buttgereit F, Smolen JS, Coogan AN, Cajochen C. Clocking in: Chronobiology in rheumatoid arthritis. Nat Rev Rheumatol 2015; 11(6): 349-56.
[http://dx.doi.org/10.1038/nrrheum.2015.31] [PMID: 25800214]
[36]
Gossan N, Boot-Handford R, Meng QJ. Ageing and osteoarthritis: A circadian rhythm connection. Biogerontology 2015; 16(2): 209-19.
[http://dx.doi.org/10.1007/s10522-014-9522-3] [PMID: 25078075]
[37]
Ortiz-Tudela E, Mteyrek A, Ballesta A, Innominato PF, Lévi F. Cancer chronotherapeutics: Experimental, theoretical, and clinical aspects. Handb Exp Pharmacol 2013; 217(217): 261-88.
[http://dx.doi.org/10.1007/978-3-642-25950-0_11] [PMID: 23604483]
[38]
Ye Y, Xiang Y, Ozguc FM, et al. The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Syst 2018; 6: 314-328.e2.
[http://dx.doi.org/10.1016/j.cels.2018.01.013]
[39]
Shanmugan P, Bandameedi R. Chronotherapeutic drug delivery systems. J Drug Metab Toxicol 2015; 6(5): 194.
[http://dx.doi.org/10.4172/2157-7609.1000194]
[40]
Librodo P, Buckley M, Luk M, Bisso A. Chronotherapeutic drug delivery. J Infus Nurs 2015; 38(S6): S18-23.
[http://dx.doi.org/10.1097/NAN.0000000000000140] [PMID: 26536406]
[41]
Javeed N, Matveyenko AV. Circadian etiology of type 2 diabetes mellitus. Physiology 2018; 33(2): 138-50.
[http://dx.doi.org/10.1152/physiol.00003.2018] [PMID: 29412061]
[42]
Khan S, Nobili L, Khatami R, et al. Circadian rhythm and epilepsy. Lancet Neurol 2018; 17(12): 1098-108.
[http://dx.doi.org/10.1016/S1474-4422(18)30335-1] [PMID: 30366868]
[43]
Ayyar VS, Sukumaran S. Circadian rhythms: Influence on physiology, pharmacology, and therapeutic interventions. J Pharmacokinet Pharmacodyn 2021; 483(48): 321-38.
[http://dx.doi.org/10.1007/s10928-021-09751-2]
[44]
Coiffard B, Diallo AB, Mezouar S, Leone M, Mege JL. A tangled threesome: Circadian rhythm, body temperature variations, and the immune system. Biology 2021; 10(1): 65.
[http://dx.doi.org/10.3390/biology10010065] [PMID: 33477463]
[45]
Musiek ES, FitzGerald GA. Molecular clocks in pharmacology. Handb Exp Pharmacol 2013; 217(217): 243-60.
[http://dx.doi.org/10.1007/978-3-642-25950-0_10] [PMID: 23604482]
[46]
Dong D, Yang D, Lin L, Wang S, Wu B. Circadian rhythm in pharmacokinetics and its relevance to chronotherapy. Biochem Pharmacol 2020; 178: 114045.
[http://dx.doi.org/10.1016/j.bcp.2020.114045] [PMID: 32446886]
[47]
Udupa N, Gupta PD. Concepts in Chronopharmacology. Jaipur, Shyam Prakashan Publishers, India 2009; p. 183.
[48]
Bruguerolle B, Valli M, Bouyard L, Jadot G, Bouyard P. Effect of the hour of administration on the pharmacokinetics of lidocaine in the rat. Eur J Drug Metab Pharmacokinet 1983; 83(8): 233-8.
[http://dx.doi.org/10.1007/BF03188753]
[49]
Wen H, Jung H, Li X. Drug delivery approaches in addressing clinical pharmacology-related issues: Opportunities and challenges. AAPS J 2015; 17(6): 1327-40.
[http://dx.doi.org/10.1208/s12248-015-9814-9] [PMID: 26276218]
[50]
Bruguerolle B, Arnaud C, Levi F, Focan C, Touitou Y, Bouvenot G. Physiopathological alterations of alpha 1 acid glycoprotein temporal variations: Implications for chronopharmacology. Prog Clin Biol Res 1989; 300: 199-214.
[PMID: 2674964]
[51]
Baydar T, Erkekoglu P. Chronopharmacokinetics of drugs in toxicological aspects: A short review for pharmacy practitioners. J Res Pharm Pract 2012; 1(1): 3-9.
[http://dx.doi.org/10.4103/2279-042X.99670] [PMID: 24991580]
[52]
Bicker J, Alves G, Falcão A, Fortuna A. Timing in drug absorption and disposition: The past, present, and future of chronopharmacokinetics. Br J Pharmacol 2020; 177(10): 2215-39.
[http://dx.doi.org/10.1111/bph.15017] [PMID: 32056195]
[53]
Silva S, Bicker J, Falcão A, Fortuna A. Antidepressants and circadian rhythm: Exploring their bidirectional interaction for the treatment of depression. Pharmaceutics 2021; 13(11): 1975.
[http://dx.doi.org/10.3390/pharmaceutics13111975] [PMID: 34834391]
[54]
Abdifetah O, Na-Bangchang K. Pharmacokinetic studies of nanoparticles as a delivery system for conventional drugs and herb-derived compounds for cancer therapy: A systematic review. Int J Nanomedicine 2019; 14: 5659-77.
[http://dx.doi.org/10.2147/IJN.S213229] [PMID: 31632004]
[55]
Feitosa RC, Geraldes DC, Beraldo-de-Araújo VL, Costa JSR, Oliveira-Nascimento L. Pharmacokinetic aspects of nanoparticle-in-matrix drug delivery systems for oral/buccal delivery. Front Pharmacol 2019; 10: 1057.
[http://dx.doi.org/10.3389/fphar.2019.01057] [PMID: 31607914]
[56]
Ciancia S, Cafarelli A, Zahoranova A, Menciassi A, Ricotti L. Pulsatile drug delivery system triggered by acoustic radiation force. Front Bioeng Biotechnol 2020; 8: 317.
[http://dx.doi.org/10.3389/fbioe.2020.00317] [PMID: 32411680]
[57]
Moore JG, Englert E Jr. Circadian rhythm of gastric acid secretion in man. Nature 1970; 226(5252): 1261-2.
[http://dx.doi.org/10.1038/2261261a0] [PMID: 5422604]
[58]
Eleftheriadis E, Kotzampassi K, Vafiadis M, Paramythiotis D. 24-hr measurement of gastric mucosal perfusion in conscious humans. Hepatogastroenterology 1998; 45(24): 2453-7.
[PMID: 9951943]
[59]
Goo RH, Moore JG, Greenberg E, Alazraki NP. Circadian variation in gastric emptying of meals in humans. Gastroenterology 1987; 93(3): 515-8.
[http://dx.doi.org/10.1016/0016-5085(87)90913-9] [PMID: 3609660]
[60]
Baraldo M. The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 2008; 4(2): 175-92.
[http://dx.doi.org/10.1517/17425255.4.2.175] [PMID: 18248311]
[61]
Bruguerolle B, Lemmer B. Recent advances in chronopharmacokinetics: Methodological problems. Life Sci 1993; 52(23): 1809-24.
[http://dx.doi.org/10.1016/0024-3205(93)90001-J] [PMID: 8502120]
[62]
Stearns AT, Balakrishnan A, Rhoads DB, Ashley SW, Tavakkolizadeh A. Diurnal rhythmicity in the transcription of jejunal drug transporters. J Pharmacol Sci 2008; 108(1): 144-8.
[http://dx.doi.org/10.1254/jphs.08100SC] [PMID: 18787306]
[63]
Wesson LG Jr. Electrolyte excretion in relation to diurnal cycles of renal function. Medicine 1964; 43: 547-92.
[64]
White CA, Pardue R, Huang C, Warren J. Chronobiological evaluation of the active biliary and renal secretion of ampicillin. Chronobiol Int 1995; 12(6): 410-8.
[http://dx.doi.org/10.3109/07420529509057290]
[65]
Ohdo S, Koyanagi S, Matsunaga N, Hamdan A. Molecular basis of chronopharmaceutics. J Pharm Sci 2011; 100(9): 3560-76.
[http://dx.doi.org/10.1002/jps.22656] [PMID: 21656520]
[66]
Chhabra VS, Tilloo SK, Walde SR, Ittadwar AM. The essentials of chronopharmacotherapeutics. Int J Pharm Pharm Sci 2012; 4: 1-8.
[67]
Dobrek L. Chronopharmacology in therapeutic drug monitoring—dependencies between the rhythmics of pharmacokinetic processes and drug concentration in blood. Pharmaceutics 2021; 13(11): 1915.
[http://dx.doi.org/10.3390/pharmaceutics13111915] [PMID: 34834330]
[68]
Vaughn B, Rotolo S, Roth H. Circadian rhythm and sleep influences on digestive physiology and disorders. Chronophysiology and therapy 2014; 4: 67-77.
[http://dx.doi.org/10.2147/CPT.S44806]
[69]
Duboc H, Coffin B, Siproudhis L. Disruption of circadian rhythms and gut motility. J Clin Gastroenterol 2020; 54(5): 405-14.
[http://dx.doi.org/10.1097/MCG.0000000000001333] [PMID: 32134798]
[70]
Cederroth CR, Albrecht U, Bass J, et al. Medicine in the fourth dimension. Cell Metab 2019; 30: 238-50.
[http://dx.doi.org/10.1016/j.cmet.2019.06.019]
[71]
Haefely W. Biological basis of drug-induced tolerance, rebound, and dependence. Contribution of recent research on benzodiazepines. Pharmacopsychiatry 1986; 19(5): 353-61.
[http://dx.doi.org/10.1055/s-2007-1025061] [PMID: 2877468]
[72]
Sharma GS, Srikanth MV, Uhumwangho MU, Phani KKS, Ramana MKV. Recent trends in pulsatile drug delivery systems - A review. Int J Drug Deliv 2010; 2(3): 200-12.
[http://dx.doi.org/10.5138/ijdd.2010.0975.0215.02030]
[73]
Saigal N, Baboota S, Ahuja A, Ali J. Site specific chronotherapeutic drug delivery systems: A patent review. Recent Pat Drug Deliv Formul 2009; 3(1): 64-70.
[http://dx.doi.org/10.2174/187221109787158328] [PMID: 19149730]
[74]
Jain D, Raturi R, Jain V, Bansal P, Singh R. Recent technologies in pulsatile drug delivery systems. Biomatter 2011; 1(1): 57-65.
[http://dx.doi.org/10.4161/biom.1.1.17717] [PMID: 23507727]
[75]
Ballesta A, Innominato PF, Dallmann R, Rand DA, Lévi FA. Systems chronotherapeutics. Pharmacol Rev 2017; 69(2): 161-99.
[http://dx.doi.org/10.1124/pr.116.013441] [PMID: 28351863]
[76]
Sajan J, Cinu TA, Chacko AJ, Litty J, Jaseeda T. Chronotherapeutics and chronotherapeutic drug delivery systems. Trop J Pharm Res 2009; 8(5): 467-75.
[http://dx.doi.org/10.4314/tjpr.v8i5.48091]
[77]
Hill RJW, Innominato PF, Lévi F, Ballesta A. Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy. PLOS Comput Biol 2020; 16(1): e1007218.
[http://dx.doi.org/10.1371/journal.pcbi.1007218] [PMID: 31986133]
[78]
Dhurke R. A review on chronomodulated drug delivery systems. Int J Recent Sci Res 2020; 11: 39578-87.
[http://dx.doi.org/10.24327/ijrsr.2020.1108.5529]
[79]
Youan BBC. Chronopharmaceutical drug delivery systems: Hurdles, hype or hope? Adv Drug Deliv Rev 2010; 62(9-10): 898-903.
[http://dx.doi.org/10.1016/j.addr.2010.04.010] [PMID: 20438781]
[80]
Kaur K, Seth N, Gill NS. Advancement in chronotherapeutic drug delivery system: Marketed technologies and current scenario. J Pharm Sci Res 2019; 11: 1984-9.
[81]
Bisht R. Chronomodulated drug delivery system: A comprehensive review on the recent advances in a new sub-discipline of ′chronopharmaceutics′. Asian J Pharm 2011; 5(1): 1-8.
[http://dx.doi.org/10.4103/0973-8398.80057]
[82]
Ranjan OP, Nayak UY, Reddy MS, Dengale SJ, Musmade PB, Udupa N. Optimization of chronomodulated delivery system coated with a blend of ethyl cellulose and Eudragit L100 by central composite design: in vitro and in vivo evaluation. J Pharm Innov 2014; 9(2): 95-105.
[http://dx.doi.org/10.1007/s12247-014-9176-3]
[83]
Isa O, Amina O. Controlled release delivery device comprising an organosol coat. Patent US10314787B2, 2006.
[84]
Baichwal AR, Woodcock P, Higgins R, Cobb J. Chronotherapeutic dosage forms and methods of treatment using chronotherapy. US20110217336A1, 2011.
[85]
Sanjay B, Shripad J, Maneesh N. Chronotherapeutic pharmaceutical composition. Patent AU2010211985A1, 2010.
[86]
Albert KS, Gana TJ, Maes J. Chronotherapeutic diltiazem formulations and the administration thereof. WO/2004/022038, 2004.
[87]
Arthur MD, Philippe RB, Arthur M. Extended release form of diltiazem. Patent US5288505A, 1991.
[88]
Newton AMJ, Kaur B, Indana VL, Rajesh KS. Chronotherapeutic drug delivery of pectin Vs. Guar Gum, Xanthan Gum Controlled release colon targeted directly compressed propranolol hcl matrix tablets. SAJ Pharm Pharmacol 2014; 1: 1-12.
[89]
Dash SK, Khan AS, Padhan A, Karna N. Formulation and evaluation of pulsatile drug delivery system of atenolol by using natural gum. Int J Pharm Sci Res 2020; 3229-42.
[90]
Verma S, Valecha V, Singh SK, Syan N. Development and evaluation of Montelukast sodium colon targeted matrix tablets based on pulsatile approach for nocturnal asthma. Int J Pharma Sci 2011; 8: 129-37.
[91]
Madhavi AV, Brahma Reddy DR, Venugopal M, Srihari N, Chenniah P, Koteswarao P. Formulation and evaluation of pulsatile drug delivery system of zafirlukast. J Drug Deliv Ther 2020; 10(2): 122-8.
[http://dx.doi.org/10.22270/jddt.v10i2.3983]
[92]
Adhikari C, Kulkarni GS, Swamy S. Formulation and evaluation of pulsatile drug delivery system of salbutamol sulfate for the chronotherapy of asthma. Asian J Pharm Clin Res 2018; 11(9): 305-11.
[http://dx.doi.org/10.22159/ajpcr.2018.v11i9.20423]
[93]
Kadam VD, Gattani SG. Development of colon targeted multiparticulate pulsatile drug delivery system for treating nocturnal asthma. Drug Deliv 2010; 17(5): 343-51.
[http://dx.doi.org/10.3109/10717541003762821] [PMID: 20429842]
[94]
Tinny T, Chacko AJ, Jose S. Formulation development and statistical optimization of chronotherapeutic tablets of indometacin. Drug Dev Ind Pharm 2013; 39(9): 1357-63.
[http://dx.doi.org/10.3109/03639045.2012.715352] [PMID: 22931205]
[95]
Thampi L, Manickem MS, Kuppuswamy S. Formulation evaluation and kinetic studies of etodolac delayed release tablets using optimized solid dispersion. Res J Pharm Technol 2018; 11(2): 445-54.
[http://dx.doi.org/10.5958/0974-360X.2018.00082.3]
[96]
Kumar PJ, Muzib YI, Misra G. Preparation and evaluation of pulsatile drug delivery of lovastatin. Res J Pharm Technol 2018; 11(7): 2797-803.
[http://dx.doi.org/10.5958/0974-360X.2018.00516.4]
[97]
Rs R. Formulation and evaluation of pulsatile drug delivery system of pregabalin. Pharm Anal Acta 2016; 7(10)
[http://dx.doi.org/10.4172/2153-2435.1000508]
[98]
Latha K, Uhumwangho MU, Sunil SA, Srikanth MV, Murthy KVR. Development of an optimised losartan potassium press-coated tablets for chronotherapeutic drug delivery. Trop J Pharm Res 2011; 10(5): 558.
[http://dx.doi.org/10.4314/tjpr.v10i5.3]
[99]
Sunil SA, Srikanth MV, Rao NS, Uhumwangho MU, Latha K, Murthy KV. Chronotherapeutic drug delivery systems: An approach to circadian rhythms diseases. Curr Drug Deliv 2011; 8(6): 622-33.
[http://dx.doi.org/10.2174/156720111797635559] [PMID: 21831038]
[100]
Fan TY, Wei SL, Yan WW, Chen DB, Li J. An investigation of pulsatile release tablets with ethylcellulose and Eudragit L as film coating materials and cross-linked polyvinylpyrrolidone in the core tablets. J Control Release 2001; 77(3): 245-51.
[http://dx.doi.org/10.1016/S0168-3659(01)00508-9] [PMID: 11733092]
[101]
Itzhak LE, Moshe F, Adel P. Delayed total release gastrointestinal drug delivery system. Patent CA2305762C, 1998.
[102]
Sunil SA, Rao NS, Srikanth MV, et al. Development and evaluation of a chronotherapeutic drug delivery system of torsemide. Braz J Pharm Sci 2011; 47(3): 593-600.
[http://dx.doi.org/10.1590/S1984-82502011000300017]
[103]
Giri S, Mohapatra S. Formulation and in vitro characterization of time release tablets of propranolol hydrochloride. Indian J Pharm Sci 2020; 82(2): 33-8.
[http://dx.doi.org/10.36468/pharmaceutical-sciences.641]
[104]
Shavi GV, Nayak UY, Reddy MS, et al. A novel long-acting biodegradable depot formulation of anastrozole for breast cancer therapy. Mater Sci Eng C 2017; 75: 535-44.
[http://dx.doi.org/10.1016/j.msec.2017.02.063] [PMID: 28415496]
[105]
Aggarwal V, Kumar R, Sharma R, Singh Y, Teotia UVS. Formulation and optimization of chronotherapeutic drug delivery from carvedilol sulphate compression coated tablets by using design of experiment approach. J Appl Pharm Sci 2013; 3: 141-6.
[http://dx.doi.org/10.7324/JAPS.2013.31025]
[106]
Kanugo AY, Kochar NI, Chandewar AV, Dhabarde DM, Dhawral VG. Design and evaluation of enteric compression-coated tablet for chronotherapeutic drug delivery. Asian J Pharm 2017; 11.
[107]
Abraham A, Mathew TS. Formulation and evaluation of enteric coated time released press coated tablets of theophylline for chronopharmacotherapy. Sch Res Libr 2012; 4: 599-606.
[108]
Nawle RB, Tadvee AA. Formulation and evaluation of time-release compression coated tablet containing acebrophylline for chronotherapy of asthma. Int J Pharm Pharm Sci 2014; 6: 231-7.
[109]
Neeharika MS, Jyothi BJ. Preparation and evaluation of zafirlukast compression coated tablets for chronotherapeutic drug delivery. J Pharm Res Int 2021; 33: 154-66.
[http://dx.doi.org/10.9734/jpri/2021/v33i32B31757]
[110]
Foppoli A, Maroni A, Palugan L, et al. Erodible coatings based on HPMC and cellulase for oral time-controlled release of drugs. Int J Pharm 2020; 585: 119425.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119425] [PMID: 32473374]
[111]
Hadi MA, Rao NGR, Rao AS. Formulation and evaluation of compression Coated tablets of Lornoxicam for Targeting early morning peak symptoms of Rheumatoid arthritis. Dhaka Univ J Pharm Sci 2014; 12(2): 109-17.
[http://dx.doi.org/10.3329/dujps.v12i2.17620]
[112]
Chandubhai PR, Abraham S, Bharath S, Madhavan V. Compression coated tablets of Flurbiprofen: A chronotherapeutic approach. J Sci Innov Res 2013; 2: 914-26.
[113]
Muzaffar S, Basha AAS, Hani U, Munawar ALMU. Formulation and evaluation of pulsatile drug delivery system using meloxicam. Int J Pharm Anal Res 2015; 1: 51-9.
[114]
Dabhi C, Randale S, Belgamwar V, Gattani S, Tekade A. Predictable pulsatile release of tramadol hydrochloride for chronotherapeutics of arthritis. Drug Deliv 2010; 17(5): 273-81.
[http://dx.doi.org/10.3109/10717541003706240] [PMID: 20524906]
[115]
Ambedkar SS, Venkata SM, Sreenivasa RN, Venkata RMK. Chronotherapeutic drug delivery from indomethacin compression coated tablets for early morning pain associated rheumatoid arthritis. Curr Drug Deliv 2013; 10(1): 109-21.
[http://dx.doi.org/10.2174/1567201811310010017] [PMID: 22974284]
[116]
Gaikwad SS, Kshirsagar SJ. Review on tablet in tablet techniques. Beni Suef Univ J Basic Appl Sci 2020; 9(1): 1-7.
[http://dx.doi.org/10.1186/s43088-019-0027-7]
[117]
Maiti S. OSDrC®: A revolution in drug formulation technology. J Pharm Sci Technol 2014; 4: 12-3.
[118]
OSDrC®. n.d. Available from: https://www.osdrc.com/
[119]
Ozeki Y, Watanabe Y, Okamoto H, Danjo K. Development of dividable one-step dry-coated tablets (dividable-OSDRC) and their evaluation as a new platform for controlled drug release. Pharm Res 2004; 21(7): 1177-83.
[http://dx.doi.org/10.1023/B:PHAM.0000033004.88953.bc] [PMID: 15290857]
[120]
Rathod S, Ram A, Thiru G. Colon targeted drug delivery systems-A Potential Approach. 2007.
[121]
Gazzaniga A, Palugan L, Foppoli A, Sangalli ME. Oral pulsatile delivery systems based on swellable hydrophilic polymers. Eur J Pharm Biopharm 2008; 68(1): 11-8.
[http://dx.doi.org/10.1016/j.ejpb.2007.05.022] [PMID: 17888641]
[122]
Kondo K, Niwa T, Ozeki Y, Ando M, Danjo K. Preparation and evaluation of orally rapidly disintegrating tablets containing taste-masked particles using one-step dry-coated tablets technology. Chem Pharm Bull 2011; 59(10): 1214-20.
[http://dx.doi.org/10.1248/cpb.59.1214] [PMID: 21963629]
[123]
Bachmann F, Koch G, Pfister M, Szinnai G, Schropp J. OptiDose: Computing the individualized optimal drug dosing regimen using optimal control. J Optim Theory Appl 2021; 189(1): 46-65.
[http://dx.doi.org/10.1007/s10957-021-01819-w] [PMID: 34720180]
[124]
Sayantany C, Sayantan S, Sabyasachi M, Somasree R. OSDrC® OptiDoseTM: A revolution in drug formulation technology - journal of advanced pharmacy education and research. J Adv Pharm Educ Res 2014; 4: 259-63.
[125]
PTIDOZ 20MG TAB ( DR REDDYS LABORATORIES LTD ) - Buy OPTIDO - MedPlusMart. n.d. Available from: https://www.medplusmart.com/product/optidoz-20mg-tab_opti0088
[126]
Phad AB, Mahale N, Chaudhari SR, Salunke KS, Phad AB. Matrix tablet: As a sustained release drug delivery system. World J Pharm Res 2014; 3: 1377-90.
[127]
Patel JK, Patel NV, Shah SH. In vitro controlled release of colon targeted mesalamine from compritol ATO 888 based matrix tablets using factorial design. Res Pharm Sci 2009; 4(2): 63-75.
[PMID: 21589801]
[128]
Mothilal M, Nithya D, Lakshmi KS, Sharanya VB. Formulation and in-vitro evaluation of osmotic drug delivery system of Metoprolol succinate. Int J Pharm Pharm Sci 2010; 2: 64-8.
[129]
Bichewar S, Pillai S, Mandloi RS, Birla N, Jain S. Formulation and evaluation of chronomodulated drug delivery system of doxofylline for treatment of nocturnal asthma. Res J Pharm Technol 2020; 13(12): 6170-5.
[http://dx.doi.org/10.5958/0974-360X.2020.01076.8]
[130]
Beg S, Swain S, Gahoi S, Kohli K. Design, development and evaluation of chronomodulated drug delivery systems of amoxicillin trihydrate with enhanced antimicrobial activity. Curr Drug Deliv 2013; 10(2): 174-87.
[http://dx.doi.org/10.2174/1567201811310020004] [PMID: 22998051]
[131]
Ranjan OP, Nayak UY, Reddy MS, Dengale SJ, Musmade PB, Udupa N. Osmotically controlled pulsatile release capsule of montelukast sodium for chronotherapy: Statistical optimization, in vitro and in vivo evaluation. Drug Deliv 2014; 21(7): 509-18.
[http://dx.doi.org/10.3109/10717544.2013.853209] [PMID: 24215165]
[132]
Zhang Y, Zhang Z, Wu F. A novel pulsed-release system based on swelling and osmotic pumping mechanism. J Control Release 2003; 89(1): 47-55.
[http://dx.doi.org/10.1016/S0168-3659(03)00092-0] [PMID: 12695062]
[133]
Patel HK, Patel U, Bhimani B, Kadikar H, Daslaniya D, Patel G. Formulation and evaluation of controlled porosity osmotic pump tablets of glimepiride. Int J Drug Deliv 2012; 4: 113-24.
[134]
Hung SF, Hsieh CM, Chen YC, Lin CM, Ho HO, Sheu MT. Formulation and process optimization of multiparticulate pulsatile system delivered by osmotic pressure-activated rupturable membrane. Int J Pharm 2015; 480(1-2): 15-26.
[http://dx.doi.org/10.1016/j.ijpharm.2015.01.006] [PMID: 25575473]
[135]
Lin H, Lin S, Lin Y, Ho H, Lo Y, Sheu M. Release characteristics and in vitro-in vivo correlation of pulsatile pattern for a pulsatile drug delivery system activated by membrane rupture via osmotic pressure and swelling. Eur J Pharm Biopharm 2008; 70(1): 289-301.
[http://dx.doi.org/10.1016/j.ejpb.2008.03.021] [PMID: 18539015]
[136]
Brindha VS, Abdul A, Sathali H, Arun K, Shanmuga PP. Swellable osmotic drug delivery system of amitriptyline hydrochloride-design and evaluation. J Curr Chem Pharm Sci 2012; 2: 55-68.
[137]
Khan Z, Choonara YE, Kumar P, du Toit LC, Ndesendo VMK, Pillay V. A novel multilayered multidisk oral tablet for chronotherapeutic drug delivery. BioMed Res Int 2013; 2013: 1-16.
[http://dx.doi.org/10.1155/2013/569470] [PMID: 24024200]
[138]
Midha KK, Teicher MH. Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulation. US6217904B1, 2000.
[139]
Sharma VK, Hussain J, Khorakiwala HF. Composition for pulsatile delivery of diltiazem and process of manufacture. US6635277B2, 2001.
[140]
Martins SM, Müller V, Galan V, Souza FP, Andreazza IF, Rosa MF. Development and evaluation of multiparticulate biphasic system for the treatment of circadian diseases. Braz J Pharm Sci 2019; 8: 54.
[141]
Chaudhari MP, Chaudhari DP. Formulation and evaluation of multiparticulate system for chronotherapeutic delivery of salbutamol sulphate. J Pharm Bioallied Sci 2012; 4(5): 71.
[http://dx.doi.org/10.4103/0975-7406.94144] [PMID: 23066213]
[142]
Kadam VD, Gattani SG. Formulation and evaluation of a pulsatile drug delivery system using time- and pH-dependant polymers. Pharm Dev Technol 2010; 15(1): 57-63.
[http://dx.doi.org/10.3109/10837450902980254] [PMID: 19552544]
[143]
Shivakumar HN, Suresh S, Desai BG. Design and evaluation of controlled onset extended release multiparticulate systems for chronotherapeutic delivery of ketoprofen. Indian J Pharm Sci 2006; 68(1): 76.
[http://dx.doi.org/10.4103/0250-474X.22969]
[144]
Ganguly Rupesh A, Suresh S, Pandit V. Multiparticulate formulation of valdecoxib for the treatment of rheumatoid arthritis. J Appl Pharm Sci 2012; 02: 217-22.
[http://dx.doi.org/10.7324/JAPS.2012.2640]
[145]
Battu S, Yalavarthi PR, Subba Reddy GV, Uma Maheswara Rao V, Jyothshna Devi K, Vadlamudi HC. Design and assessment of pulsatile technology based chronomodulated delivery systems of nifedipine. Beni Suef Univ J Basic Appl Sci 2018; 7(4): 441-5.
[http://dx.doi.org/10.1016/j.bjbas.2018.03.012]
[146]
Nayak UY, Shavi GV, Nayak Y, et al. Chronotherapeutic drug delivery for early morning surge in blood pressure: A programmable delivery system. J Control Release 2009; 136(2): 125-31.
[http://dx.doi.org/10.1016/j.jconrel.2009.02.008] [PMID: 19239918]
[147]
Hadi MA, Raghavendra RNG, Srinivasa RA. Formulation and evaluation of ileo-colonic targeted matrix-mini-tablets of Naproxen for chronotherapeutic treatment of rheumatoid arthritis. Pak J Pharm Sci 2015; 28: 185-93.
[http://dx.doi.org/10.1016/j.jsps.2015.03.001] [PMID: 25553695]
[148]
Cerciello A, Auriemma G, Morello S, Aquino RP, Del Gaudio P, Russo P. Prednisolone delivery platforms: Capsules and beads combination for a right timing therapy. PLoS One 2016; 11(7): e0160266.
[http://dx.doi.org/10.1371/journal.pone.0160266] [PMID: 27472446]
[149]
Mastiholimath VS, Dandagi PM, Jain SS, Gadad AP, Kulkarni AR. Time and pH dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma. Int J Pharm 2007; 328(1): 49-56.
[http://dx.doi.org/10.1016/j.ijpharm.2006.07.045] [PMID: 16942847]
[150]
Nagaraja G, Agarwal S, Shenoy D, Minhas PS, Yogesh DB, Baig F. Design and evaluation of time programmed pulsincap. J Chem Pharm Res 2013; 5: 76-87.
[151]
Watts Peter. Colonic drug delivery composition. Patent US6228396B1, 1995.
[152]
Ansari KA, Pagar KP, Anwar S, Vavia PR. Design and optimization of self-microemulsifying drug delivery system (SMEDDS) of felodipine for chronotherapeutic application. Braz J Pharm Sci 2014; 50(1): 203-12.
[http://dx.doi.org/10.1590/S1984-82502011000100021]
[153]
Beth AB, Xiaodi G, Kimberly F, et al. Oral pulsed dose drug delivery system. Patent US6605300B1, 1999.
[154]
Beth A, Xiaodi G, Kimberly F, et al. Oral pulsed dose drug delivery system. Patent US6322819B1, 1998.
[155]
Patil SS, Shahiwala A. Patented pulsatile drug delivery technologies for chronotherapy. Expert Opin Ther Pat 2014; 24: 845-56.
[http://dx.doi.org/10.1517/13543776.2014.916281]
[156]
Phillip JP, Krishna DV, Ponrathnam S, Venkatesh DYL. Timed pulsatile drug delivery systems. Patent US7048945B2, 2003.
[157]
Sher P, Ingavle G, Ponrathnam S, Benson JR, Li NH, Pawar AP. Novel/conceptual floating pulsatile system using high internal phase emulsion based porous material intended for chronotherapy. AAPS PharmSciTech 2009; 10(4): 1368-80.
[http://dx.doi.org/10.1208/s12249-009-9331-1] [PMID: 19936939]
[158]
Jagdale SC, Sali MS, Barhate AL, Kuchekar BS, Chabukswar AR. Formulation, development, and evaluation of floating pulsatile drug delivery system of atenolol. PDA J Pharm Sci Technol 2013; 67(3): 214-28.
[http://dx.doi.org/10.5731/pdajpst.2013.00916] [PMID: 23752749]
[159]
Suddala SG, Sahoo SK, Yamsani MR. Development and evaluation of floating pulsatile drug delivery system using meloxicam. Int J Drug Deliv Technol 2017; 7(4): 244-54.
[http://dx.doi.org/10.25258/ijddt.v7i04.10647]
[160]
Jagdale SC, Pawar CR. Application of design of experiment for polyox and xanthan gum coated floating pulsatile delivery of sumatriptan succinate in migraine treatment. Biomed Res Int 2014; 2014: 547212.
[http://dx.doi.org/10.1155/2014/547212]
[161]
Shukla D, Chakraborty S, Mishra B. In vitro and in vivo evaluation of multilayered pastilles for chronotherapeutic management of nocturnal asthma. Expert Opin Drug Deliv 2012; 9(1): 9-18.
[http://dx.doi.org/10.1517/17425247.2012.638915] [PMID: 22118427]
[162]
Xie J, Li A, Li J. Advances in pH-sensitive polymers for smart insulin delivery. Macromol Rapid Commun 2017; 38(23): 1700413.
[http://dx.doi.org/10.1002/marc.201700413] [PMID: 28976043]
[163]
Soni ML, Namdeo KP, Jain SK, et al. pH-enzyme di-dependent chronotherapeutic drug delivery system of theophylline for nocturnal asthma. Chem Pharm Bull 2011; 59(2): 191-5.
[http://dx.doi.org/10.1248/cpb.59.191] [PMID: 21297298]
[164]
Das S, Ghosh B, Basu S. Formulation and evaluation of pulsatile drug delivery system of atenolol. J Basic Appl Res Biomed 2022; 6(1): 45-9.
[http://dx.doi.org/10.51152/JBARBIOMED.V6I1.8]
[165]
Chandrasekhara S, Nagesh C, Praveen K, Rekha S. Using pH sensitive polymer. Am J Adv Drug Deliv 2013; 1: 635-50.
[166]
Jaswanth Gowda BH, Shankar SJ, Munisamy M, Akshatha RS, Sagar VS. Development of ph-dependent chronomodulated delivery systems of 5-fluorouracil and oxaliplatin to treat colon cancer. Int J Appl Pharm 2020; 12: 118-30.
[http://dx.doi.org/10.22159/ijap.2020v12i5.38156]
[167]
Lin SY. Thermoresponsive gating membranes embedded with liquid crystal(s) for pulsatile transdermal drug delivery: An overview and perspectives. J Control Release 2020; 319: 450-74.
[http://dx.doi.org/10.1016/j.jconrel.2019.12.046] [PMID: 31901369]
[168]
Liu DE, Chen Q, Long YB, Ma J, Gao H. A thermo-responsive polyurethane organogel for norfloxacin delivery. Polym Chem 2018; 9(2): 228-35.
[http://dx.doi.org/10.1039/C7PY01803G]
[169]
Chih-Ming C. Diltiazem controlled release formulation. Patent US5834023A, 1996.
[170]
Harry E, Danna LR, Robert KS, John CC, Mark KD. Functionalized nanostructured films. CA2216378A1, 1996.
[171]
Anal AK, Stevens WF, Remuñán-López C. Ionotropic cross-linked chitosan microspheres for controlled release of ampicillin. Int J Pharm 2006; 312(1-2): 166-73.
[http://dx.doi.org/10.1016/j.ijpharm.2006.01.043] [PMID: 16497452]
[172]
Patel P, Dhake A. Design and development of colon specific microspheres for chronotherapy of hypertension. J Pharm Bioallied Sci 2012; 4(5): 33.
[http://dx.doi.org/10.4103/0975-7406.94132] [PMID: 23066197]
[173]
Ashvini VRU, Kavitha K, Sockan GN, Microspheres A. An unique system as drug delivery carriers for non steroidal anti-inflammatory drugs. Int J Pharm Sci Rev Res 2010; 5: 10-7.
[174]
Mahale MM, Saudagar RB. Microsphere: A review. J Drug Deliv Ther 2019; 9: 854-6.
[http://dx.doi.org/10.22270/JDDT.V9I3-S.2826]
[175]
Azagheswari B, Kuriokase SP, Padma SP, Azagheswari B. A review on microcapsules. Glob J Pharmacol 2015; 9: 28-39.
[http://dx.doi.org/10.5829/idosi.gjp.2015.9.1.91110]
[176]
Nisha S, Neha P, Chandra GP, Microspheres ADCFC. Drug delivery: A Review. Int J Pharm Sci Res 2015; 4579-87.
[177]
Sree Giri Prasad B, Gupta VRM, Devanna N, Jayasurya K. Microspheres as Drug delivery system - a review. J Glob Trends Pharm Sci 2014; 5: 1961-72.
[178]
Taneja R, Gupta GD. In-vitro study of amlodipine and nifedipine drugs of pulsatile drug delivery system. Int J Pharm Sci Res 2017; 8: 1820.
[179]
Taneja R, Gupta GD. Development and characterization pulsatile microspheres of nifedipine for hypertension. Recent Pat Drug Deliv Formul 2017; 11(1): 67-76.
[http://dx.doi.org/10.2174/1872211311666170213104321] [PMID: 28201961]
[180]
Patel KT, Mahajan AN, Shah DA. Studies in formulation development of chronotherapeutics dosage of model drug. Pharm Lett 2011; 3: 277-40.
[181]
Bansal A, Pande V. Development and evaluation of dual cross-linked pulsatile beads for chronotherapy of rheumatoid arthritis. J Pharm 2013; 2013: 1-8.
[http://dx.doi.org/10.1155/2013/906178]
[182]
Kamble D, Singhavi D, Tapadia S, Khan S. Investigation of pectin-hydroxypropyl methylcellulose-coated floating beads for pulsatile release of piroxicam. Turk J Pharm Sci 2020; 17(5): 542-8.
[http://dx.doi.org/10.4274/tjps.galenos.2019.99896] [PMID: 33177936]
[183]
Vishwajeet G, Salunkhe AK, Dias RJ, Mali KK. Formulation and evaluation of floating pulsatile drug delivery system of Metoprolol tartrate. Pharm Lett 2011; 3: 147-60.
[184]
Zou H, Jiang X, Kong L, Gao S. Design and evaluation of a dry coated drug delivery system with floating-pulsatile release. J Pharm Sci 2008; 97(1): 263-73.
[http://dx.doi.org/10.1002/jps.21083] [PMID: 17803198]
[185]
Sundara RB, Bodiwala J, Isaac SP. Formulation and evaluation of chitosan prazosin beads by ionotropic gelation method. Int J Res Pharm Chem 2012; 2: 974-83.
[186]
Badve SS, Sher P, Korde A, Pawar AP. Development of hollow/porous calcium pectinate beads for floating-pulsatile drug delivery. Eur J Pharm Biopharm 2007; 65(1): 85-93.
[http://dx.doi.org/10.1016/j.ejpb.2006.07.010] [PMID: 16971097]
[187]
Auriemma G, Cerciello A, Aquino RP, Del Gaudio P, Fusco BM, Russo P. Pectin and Zinc Alginate: The right inner/outer polymer combination for core-shell drug delivery systems. Pharmaceutics 2020; 12(2): 87.
[http://dx.doi.org/10.3390/pharmaceutics12020087] [PMID: 31972993]
[188]
Singh S, Koland M. Formulation and evaluation of pulsatile drug delivery systems of glipizide for the management of type-II diabetes mellitus. J Drug Deliv Ther 2016; 6(1): 11-8.
[http://dx.doi.org/10.22270/jddt.v6i1.1192]
[189]
Ramasamy T, Ruttala HB, Shanmugam S, Umadevi SK. Eudragit-coated aceclofenac-loaded pectin microspheres in chronopharmacological treatment of rheumatoid arthritis. Drug Deliv 2013; 20(2): 65-77.
[http://dx.doi.org/10.3109/10717544.2012.762434] [PMID: 23537465]
[190]
Ganesh NS, Deecaraman D. Chronomodulated drug delivery system of lornoxicam using natural polymer. J Pharm Res 2011; 825-8.
[191]
Amrutkar JR, Gattani SG. A novel hydrogel plug of Sterculia urens for pulsatile delivery: in vitro and in vivo evaluation. J Microencapsul 2012; 29(1): 72-82.
[http://dx.doi.org/10.3109/02652048.2011.629789] [PMID: 22034955]
[192]
Zielińska A, Carreiró F, Oliveira AM, et al. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology. Molecules 2020; 25(16): 3731.
[http://dx.doi.org/10.3390/molecules25163731] [PMID: 32824172]
[193]
Muralidharan P, Malapit M, Mallory E, Hayes D Jr, Mansour HM. Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine 2015; 11(5): 1189-99.
[http://dx.doi.org/10.1016/j.nano.2015.01.007] [PMID: 25659645]
[194]
Satarkar N, Hilt J. Magnetic hydrogel nanocomposites for remote controlled pulsatile drug release. J Control Release 2008; 130(3): 246-51.
[http://dx.doi.org/10.1016/j.jconrel.2008.06.008] [PMID: 18606201]
[195]
Hu SH, Liu TY, Liu DM, Chen SY. Controlled pulsatile drug release from a ferrogel by a high-frequency magnetic field. Macromolecules 2007; 40(19): 6786-8.
[http://dx.doi.org/10.1021/ma0707584]
[196]
Hu J, Fu S, Peng Q, et al. Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation. Int J Pharm 2017; 516(1-2): 313-22.
[http://dx.doi.org/10.1016/j.ijpharm.2016.11.047] [PMID: 27884713]
[197]
Yang J, Zhai S, Qin H, Yan H, Xing D, Hu X. NIR-controlled morphology transformation and pulsatile drug delivery based on multifunctional phototheranostic nanoparticles for photoacoustic imaging-guided photothermal-chemotherapy. Biomaterials 2018; 176: 1-12.
[http://dx.doi.org/10.1016/j.biomaterials.2018.05.033] [PMID: 29842986]
[198]
Dragojevic S, Ryu J, Raucher D, Rades T, Grohganz H, Löbmann K. Polymer-based prodrugs: Improving tumor targeting and the solubility of small molecule drugs in cancer therapy. Molecules 2015; 20(12): 21750-69.
[http://dx.doi.org/10.3390/molecules201219804] [PMID: 26690101]
[199]
Lee Y, Kim IH, Kim J, et al. Evaluation of dextran-flufenamic acid ester as a polymeric colon-specific prodrug of flufenamic acid, an anti-inflammatory drug, for chronotherapy. J Drug Target 2011; 19(5): 336-43.
[http://dx.doi.org/10.3109/1061186X.2010.499462] [PMID: 20615092]
[200]
Allen J, Wang J, Zolotarskaya OY, et al. PEAMOtecan, a novel chronotherapeutic polymeric drug for brain cancer. J Control Release 2020; 321: 36-48.
[http://dx.doi.org/10.1016/j.jconrel.2020.02.003] [PMID: 32027939]
[201]
Gopalbhai PB, Himanshu S, Kyatanwar A. Recent techniques for oral time controlled pulsatile technology. Int J Res Pharm Biomed Sci 2009; 3: 118-24.
[202]
Nitin GD, Kadam VJ, Jadhav K, Kyatanwar A, Nitin G. Pulsatile drug delivery system. Int J Res Pharm Biomed Sci 2012; 3: 118-24.
[203]
Conte U, Maggi L. Modulation of the dissolution profiles from Geomatrix® multi-layer matrix tablets containing drugs of different solubility. Biomaterials 1996; 17(9): 889-96.
[http://dx.doi.org/10.1016/0142-9612(96)83284-4] [PMID: 8718934]
[204]
Staniforth JN, Baichwal AR. TIMERx®: Novel polysaccharide composites for controlled/programmed release of drugs in the gastrointestinal tract. Expert Opin Drug Deliv 2005; 2(3): 587-95.
[http://dx.doi.org/10.1517/17425247.2.3.587] [PMID: 16296777]
[205]
Devane JG, Butler J, Mulligan S. IPDAS: A novel technology brings new benefits when applied to naproxen sodium. Am J Orthop 1996; 25(S9): 7-13.
[PMID: 8886212]
[206]
Managuli RS, Wang JT, Faruqu FN, et al. Asenapine maleate-loaded nanostructured lipid carriers: Optimization and in vitro, ex vivo and in vivo evaluations. Nanomedicine 2019; 14(7): 889-910.
[http://dx.doi.org/10.2217/nnm-2018-0289] [PMID: 30874464]
[207]
Dey NS, Majumdar S, Rao MEB. Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res 2008; 7(3): 1075.
[http://dx.doi.org/10.4314/tjpr.v7i3.14692]
[208]
Levina M, Voung H, Rajabi-Siahboomi AR. Mini-tabs: Versatile multiparticulate option for oral drug delivery. Adv Deliv Sci Technol 2017; 95-118.
[http://dx.doi.org/10.1007/978-1-4939-7012-4_5]
[209]
Ueda S, Ibuki R, Kawamura A, et al. Development of a novel drug delivery system, time-controlled explosion system (TES). IV. in vivo drug release behavior. J Drug Target 1994; 2(2): 133-40.
[http://dx.doi.org/10.3109/10611869409015901] [PMID: 8069590]
[210]
Ueda S, Hata T, Asakura S, Yamaguchi H, Kotani M, Ueda Y. Development of a novel drug release system, time-controlled explosion system (TES). I. Concept and design. J Drug Target 1994; 2(1): 35-44.
[http://dx.doi.org/10.3109/10611869409015891] [PMID: 8069582]
[211]
Ramteke KH, Jadhav VB, Dhole SN. Microspheres: As carrieres used for novel drug delivery system. IOSR J Pharm 2012; 2: 44-8.
[http://dx.doi.org/10.9790/3013-24204448]
[212]
Ting R, Hsiao C. Press coated, pulsatile drug delivery system suitable for oral administration. Patent WO/1999/051209, 1999.
[213]
Ting R, Hsiao C. Multiplex drug delivery system suitable for oral administration. Patent WO2000018447, 2000.
[214]
Jones WJ III, Francis JJ. Softgels: Consumer perceptions and market impact relative to other oral dosage forms. Adv Ther 2000; 17(5): 213-21.
[http://dx.doi.org/10.1007/BF02853160] [PMID: 11186141]
[215]
Verma RK, Garg S. Drug delivery technologies and future directions. Pharm Technol 2001; 25: 1-14.
[216]
Santini JT Jr, Richards AC, Scheidt R, Cima MJ, Langer R. Microchips as controlled drug-delivery devices. Angew Chem Int Ed 2000; 39(14): 2396-407.
[http://dx.doi.org/10.1002/1521-3773(20000717)39:14<2396::AID-ANIE2396>3.0.CO;2-U] [PMID: 10941095]
[217]
Sershen S, West J. Implantable, polymeric systems for modulated drug delivery. Adv Drug Deliv Rev 2002; 54(9): 1225-35.
[http://dx.doi.org/10.1016/S0169-409X(02)00090-X] [PMID: 12393303]
[218]
Lévi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350(9079): 681-6.
[http://dx.doi.org/10.1016/S0140-6736(97)03358-8] [PMID: 9291901]
[219]
von Roemeling R, Hrushesky WJ. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol 1989; 7(11): 1710-9.
[http://dx.doi.org/10.1200/JCO.1989.7.11.1710] [PMID: 2530318]
[220]
Tzannis ST, Hrushesky WJ, Wood PA, Przybycien TM. Irreversible inactivation of interleukin 2 in a pump-based delivery environment. Proc Natl Acad Sci 1996; 93(11): 5460-5.
[http://dx.doi.org/10.1073/pnas.93.11.5460] [PMID: 8643597]

Rights & Permissions Print Cite
Article Metrics
49
2
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy